Spyre Therapeutics, Inc. (SYRE)

Market Cap	1.07B
Revenue (ttm)	n/a
Net Income (ttm)	-149.56M
Shares Out	60.28M
EPS (ttm)	-3.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	773,113
Open	17.06
Previous Close	17.02
Day's Range	16.73 - 17.91
52-Week Range	16.71 - 40.84
Beta	2.99
Analysts	Strong Buy
Price Target	51.50 (+191.45%)
Earnings Date	May 8, 2025

About SYRE

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-α4β7) and SPY...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRE
• Website: https://www.spyre.com

Analyst Forecast

According to 8 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price forecast is $51.5, which is an increase of 191.45% from the latest price.

Price Target

$51.5

(191.45% upside)

Analyst Consensus: Strong Buy